The role of phenotyping and replication capacity in anti-HIV therapeutics

Current Opinion in Molecular Therapeutics

Volumn 6, Issue 3, 2004, Pages 308-317

  Baliga, Christopher S ^a   Sutton, Richard E ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

HIV; Phenotype; Replication capacity; Therapy

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; LAMIVUDINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR;

ASSAY; CLINICAL TRIAL; DISEASE MARKER; DRUG SENSITIVITY; EVIDENCE BASED MEDICINE; EXPERIENCE; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNE SYSTEM; LYMPHOCYTE COUNT; MULTIDRUG RESISTANCE; NONHUMAN; PHENOTYPE; REVIEW; STANDARD; T LYMPHOCYTE; VIROLOGY; VIRUS LOAD; VIRUS REPLICATION; VIRUS RESISTANCE;

ACQUIRED IMMUNODEFICIENCY SYNDROME; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; ANTIVIRAL AGENTS; CD4 LYMPHOCYTE COUNT; DRUG RESISTANCE, VIRAL; HIV; HIV SEROPOSITIVITY; HUMANS; PHENOTYPE; VIRAL LOAD; VIRUS REPLICATION;

EID: 3242891693     PISSN: 14648431     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (45)

1. Golin CE, Liu H, Hays RD, Miller LG, Beck CK, Ickovics J, Kaplan AH, Wenger NS: A prospective study of predictors of adherence to combination antiretroviral medication. J Gen Intern Med (2002) 17(10):756-765.
2. UNAIDS: AIDS Epidemic Update. UNAIDS (2003).
3. Centers for Disease Control and Prevention: HIV/AIDS Sureveillance Report. (2002) 14.
4. Bates M, Wrin T, Huang W, Petropoulos C, Hellmann N: Practical applications of viral fitness in clinical practice. Curr Opin Infect Dis (2003) 16(1):11-18.
5. Nijhuis M, Deeks S, Boucher C: Implications of antiretroviral resistance on viral fitness. Curr Opin Infect Dis (2001) 14(1):23-28.
6. Resch W, Ziermann R, Parkin N, Gamamik A, Swanstrom R: Nelfinavir-resistant, amprenavir-hypersusceptible strains of human immunodeficiency virus type 1 carrying an N88S mutation in protease have reduced infectivity, reduced replication capacity, and reduced fitness and process Gag polyprotein precursor aberrantly. J Virol (2002) 76(17):8659-8666.
7. Barbour JD, Wrin T, Grant RM, Martin JN, Segal MR, Petropoulos CJ, Deeks SG: Evolution of phenotypic drug susceptibility and viral replication capacity during long-term virologic failure of protease inhibitor therapy in human immunodeficiency virus-infected adults. J Virol (2002) 76(21):11104-11112.
8. Huang W, Gamarnik A, Limoli K, Petropoulos CJ, Whitcomb JM: Amino acid substitutions at position 190 of human immunodeficiency virus type 1 reverse transcriptase increase susceptibility to delavirdine and impair virus replication. J Virol (2003) 77(2):1512-1523.
9. Perno CF, Ceccherini-Silberstein F, De Luca A, Cozzi-Lepri A, Gori C, Cingolani A, Bellocchi MC, Trotta MP, Piano P, Forbici F, Scasso A et al: Virologic correlates of adherence to antiretroviral medications and therapeutic failure. J Acquir Immune Defic Syndr (2002) 31(Suppl 3):S118-S122.
10. Larder BA, Chesebro B, Richman DD: Susceptibilities of zidovudine-susceptible and -resistant human immunodeficiency virus isolates to antiviral agents determined by using a quantitative plaque reduction assay. Antimicrob Agents Chemother (1990) 34(3):436-441.
11. Larder BA, Darby G, Richman DD: HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science (1989) 243(4899):1731-1734.
12. Berger EA, Doms RW, Fenyo EM, Korber BT, Littman DR, Moore JP, Sattentau QJ, Schuitemaker H, Sodroski J, Weiss RA: A new classification of HIV-1. Nature (1998) 391(6664):240.
13. Eron JJ, Gorczyca P, Kaplan JC, D'Aquila RT: Susceptibility testing by polymerase chain reaction DNA quantitation: A method to measure drug resistance of human immunodeficiency virus type 1 isolates. Proc Natl Acad Sci USA (1992) 89(8):3241-3245.
14. Japour AJ, Chatis PA, Eigenrauch HA, Crumpacker CS: Detection of human immunodeficiency virus type 1 clinical isolates with reduced sensitivity to zidovudine and dideoxyinosine by RNA.RNA hybridization. Proc Natl Acad Sci USA (1991) 88(8):3092-3096.
15. Brun-Vezinet F, Ingrand D, Deforges L, Gochi K, Ferchall F, Schmitt MP, Jung M, Masquelier B, Aubert J, Buffet-Janvresse C, Fleury H: HIV-1 sensitivity to zidovudine: A consensus culture technique validated by genotypic analysis of the reverse transcriptase. J Virol Methods (1992) 37(2):177-188.
16. Japour AJ, Mayers DL, Johnson VA, Kuritzkes DR, Beckett LA, Arduino JM, Lane J, Black RJ, Reichelderfer PS, D'Aquila RT, Crumpacker C et al: Standardized peripheral blood mononuclear cell culture assay for determination of drug susceptibilities of clinical human immunodeficiency virus type 1 isolates. The RV-43 Study Group, The AIDS Clinical Trials Group Virology Committee Resistance Working Group. Antimicrob Agents Chemother (1993) 37(5):1095-1101.
17. Kusumi K, Conway B, Cunningham S, Berson A, Evans C, Iversen AK, Colvin D, Gallo MV, Coutre S, Shpaer EG, Faulkner D et al: Human immunodeficiency virus type 1 envelope gene structure and diversity in vivo and after cocultivation in vitro. J Virol (1992) 66(2):875-885.
18. Vartanian J, Meyerhans A, Asjo B, Wain-Hobson S: Selection recombination and G - A hypermutation of human immunodeficiency type 1 genomes. J Virol (1991) 65(4):1779-1788.
19. Kellam P, Larder BA: Recombinant virus assay: A rapid, phenotypic assay for assessment of drug susceptibility of human immunodeficiency virus type 1 isolates. Antimicrob Agents Chemother (1994) 38(1):23-30.
20. Kozal W, Shafer RW, Winters MA, Katzenstein DA, Merigan TC: A mutation in human immunodeficiency virus reverse transcriptase and decline in CD4 lymphocyte numbers in long-term zidovudine recipients. J Infect Dis (1993) 167(3):526-532.
21. Schuurman R, Nijhuis M, van Leeuwen R, Schipper P, de Jong D, Collis P, Danner SA, Mulder J, Loveday C, Christopherson C et al: Rapid changes in human immunodeficiency virus type 1 RNA load and appearance of drug-resistant virus populations in persons treated with lamivudine (3TC). J Infect Dis (1995) 171(6):1411-1419.
22. Boucher CA, Keulen W, van Bommel T, Nijhuis M, de Jong D, de Jong MD, Schipper P, Back NK: Human immunodeficiency virus type 1 drug susceptibility determination by using recombinant viruses generated from patient sera tested in a cell-killing assay. Antimicrob Agents Chemother (1996) 40(10):2404-2409.
23. Paolucci S, Baldanti F, Zavattoni M, Comolli G, Labò N, Menzo S, Clementi M, Gerna G: Comparison of levels of HIV-1 resistance to protease inhibitors by recombinant versus conventional virus phenotypic assay and two genotypic interpretation procedures in treatment-naive and HAART-experienced HIV-infected patients. J Antimicrob Agents Chemother (2003) 51(1):135-139.
24. Hertogs K, de Bethune MP, Miller V, Ivens T, Schel P, Van Cauwenberge A, Van Den Eynde C, Van Gerwen V, Azijn H , Van Houtte M, Peeters F et al: A rapid method for simultaneous detection of phenotypic resistance inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs. Antimicrob Agents Chemother (1998) 42(2):269-276.
25. Petropoulos CJ, Parkin NT, Limoli KL, Lie YS, Wrin T, Huang W, Tian H, Smith D, Winslow GA, Capon DJ, Whitcomb JM: A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrob Agents Chemother (2000) 44(4):920-928.
26. Parkin N, Chappey C, Maroldo L, Bates M, Hellmann NS, Petropoulos CJ: Phenotypic and genotypic HIV-1 drug resistance assays provide complementary information. J Acquir Immune Defic Syndr (2002) 31(2):128-136.
27. Parkin NT, Hellmann NS, Whitcomb JM, Kiss L, Chappey C, Petropoulos CJ: Natural variation of drug susceptibility in wild-type human immunodeficiency virus type 1. Antimicrob Agents Chemother (2004) 48(2):437-443.
28. Qari SH, Respess R, Weinstock H, Beltrami EM, Hertogs K, Larder BA, Petropoulos CJ, Hellmann N, Heneine W: Comparative analysis of two commercial phenotypic assays for drug susceptibility testing of human immunodeficiency virus type 1. J Clin Microbiol (2002) 40(1):31-35.
29. Robinson LH, Gale CV, Kleim JP: Inclusion of full length human immunodeficiency virus type 1 (HIV-1) gag sequences in viral recombinants applied to drug susceptibility phenotyping. J Virol Methods (2002) 104(2):147-160.
30. Gehringer H, Von der Helm K, Seelmeir S, Weissbrich B, Eberle J, Nitschko H: Development and evaluation of a phenotypic assay monitoring resistance formation to protease inhibitors in HIV-1-infected patients. J Virol Methods (2003) 109(2):143-152.
31. Call SA, Saag MS, Westfall AO, Raper JL, Pham SV, Tolson JM, Hellmann NS, Cloud GA, Johnson VA: Phenotypic drug susceptibility testing predicts long-term virologic suppression better than treatment history in patients with human immunodeficiency virus infection. J Infect Dis (2001) 183(3):401-408.
32. Katzenstein DA, Bosch RJ, Hellmann N, Wang N, Bacheler L, Albrecht MA: Phenotypic susceptibility and virological outcome in nucleoside-experienced patients receiving three or four antiretroviral drugs. AIDS (2003) 17(6):821-830.
33. Cohen CJ, Hunt S, Sension M, Farthing C, Conant M, Jacobson S, Nadler J, Verbiest W, Hertogs K, Ames M, Rinehart AR et al: A randomized trial assessing the impact of phenotypic resistance testing on antiretroviral therapy. AIDS (2002) 16(4):579-588.
34. Vray M, Meynard JL, Dalban C, Morand-Joubert L, Clavel F, Brun-Vezinet F, Peytavin G, Costagliola D, Girard PM: Predictors of virological response to a change in the antiretroviral treatment regimen in HIV-1-infected patients enrolled in a randomized trial comparing genotyping, phenotyping and standard of care (Narval trial, ANRS 088). Antivir Ther (2003) 8(5):427-434.
35. Wegner SA, Wallace MR, Aronson NE, Tasker SA, Blazes DL, Tamminga C, Fraser S, Dolan MJ, Stephan KT, Michael NL, Jagodzinski LL et al: Long-term efficacy of routine access to antiretroviral-resistance testing in HIV type 1-infected patients: Results of the clinical efficacy of resistance testing trial. Clin Infect Dis (2004) 38(5):723-730.
36. Graham N, Peeters M, Vergiest W, Harrigan R, Larder B: The virtual phenotype is an independent predictor of clinical response. Antivir Ther (2001) 6(Suppl 1):32.
37. Verbiest W, Peeters M, Hertogs K, Schel P, Bloor S, Rinehart A, Graham N, Cohen C, Larder BA: Virtual phenotype is concordant with actual phenotype: A retrospective analysis of data from VIRA3001. Antivir Ther (2000) 5(Suppl 3):Abs 81.
38. Mazzotta F, Lo Caputo S, Torti C, Tinelli C, Pierotti P, Castelli F, Lazzarin A, Angarano G, Maserati R, Gianotti N, Ladisa N et al: Real versus virtual phenotype to guide treatment in heavily pretreated patients: 48-Week follow-up of the Genotipo-Fenotipo di Resistenza (GenPheRex) trial. J Acquir Immune Defic Syndr (2003) 32(3):268-280.
39. Torti C, Quiros-Roldan E, Keulen W, Scudeller L, Lo Caputo S, Boucher C, Castelli F, Mazzotta F, Pierotti P, Been-Tiktak AM, Buccoliero G et al: Comparison between rules-based human immunodeficiency virus type 1 genotype interpretations and real or virtual phenotype: Concordance analysis and correlation with clinical outcomes in heavily treated patients. J Infect Dis (2003) 188(2):194-201.
40. Perez-Elias M, Garcia-Arota I, Munoz V, Santos I, Sanz J, Abraira V, Arribas JR, Gonzalez J, Moreno A, Dronda F, Antela A et al: Phenotype or virtual phenotype for choosing antiretroviral therapy after failure: A prospective randomized study. Antivir Ther (2003) 8(6):577-584.
41. Deeks SG, Wrin T, Liegler T, Hoh R, Hayden M, Barbour JD, Hellmann NS, Petropoulos CJ, McCune JM, Hellerstein MK, Grant RM: Virologic and immunologic consequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. N Engl J Med (2001) 344(7):472-480.
42. Prado JG, Wrin T, Beauchaine J, Ruiz L, Petropoulos CJ, Frost SD, Clotet B, D'Aquila RT, Martinez-Picado J: Amprenavir-resistant HIV-1 exhibits lopinavir cross-resistance and reduced replication capacity. AIDS (2002) 16(7):1009-1017.
43. Campbell TB, Schneider K, Wrin T, Petropolous CJ, Connick E: Relationship between in vitro human immunodeficiency virus type 1 replication rate and virus load in plasma. J Virol (2003) 77(22):12105-12112.
44. Little SJ, Frost SD, Routy JP, Collier AC, Margolick JB, Daar ES, Koup RA, Conway B, Wang L, Wrin T, Petropoulos CJ et al: High replication capacity is associated with high baseline viral load in untreated subjects with primary HIV infection. Int Conf Retroviruses Opportunistic Infect (2003) 10:Abs 152.
45. Deeks SG, Grant RM, Wrin T, Paxinos EE, Liegler T, Hoh R, Martin JN, Petropoulos CJ : Persistence of drug-resistant HIV-1 after a structured treatment interruption and its impact on treatment response. AIDS (2003) 17(3):361-370.